keyword
MENU ▼
Read by QxMD icon Read
search

Uterine serous cancer

keyword
https://www.readbyqxmd.com/read/27926776/synuclein-%C3%AE-in-uterine-serous-carcinoma-impacts-survival-an-nrg-oncology-gynecologic-oncology-group-study
#1
Abigail D Winder, Kruti P Maniar, Jian-Jun Wei, Dachao Liu, Denise M Scholtens, John R Lurain, Julian C Schink, Barbara M Buttin, Virginia L Filiaci, Heather A Lankes, Nilsa C Ramirez, Kay Park, Meenakshi Singh, Richard W Lieberman, Robert S Mannel, Matthew A Powell, Floor J Backes, Cara A Mathews, Michael L Pearl, Angeles Alvarez Secord, David J Peace, David G Mutch, William T Creasman, J Julie Kim
BACKGROUND: Synuclein-γ (SNCG) is highly expressed in advanced solid tumors, including uterine serous carcinoma (USC). The objective of the current study was to determine whether SNCG protein was associated with survival and clinical covariates using the largest existing collection of USCs from the Gynecologic Oncology Group (GOG-8023). METHODS: High-density tissue microarrays (TMAs) of tumor tissues from 313 patients with USC were stained by immunohistochemistry for SNCG, p53, p16, FOLR1, pERK, pAKT, ER, PR, and HER2/neu...
December 7, 2016: Cancer
https://www.readbyqxmd.com/read/27921006/survival-and-control-prognosticators-of-recurrent-gynecological-malignancies-of-the-pelvis-and-para-aortic-region-treated-with-stereotactic-body-radiation-therapy
#2
Shaakir Hasan, Anthony Ricco, Kaylette Jenkins, Rachelle Lanciano, Alexandra Hanlon, John Lamond, Jun Yang, Jing Feng, Michael Good, Joel Noumoff, Luther Brady
PURPOSE: To define prognostic factors associated with improved survival and local control (LC) for gynecologic cancer recurrences limited to the pelvis and para-aortic (PA) region using stereotactic body radiation therapy (SBRT). METHODS: Between 2/2008 and 7/2014, 30 women (35 targets) with pelvic or PA recurrence of endometrioid (n = 12), cervical (n = 11), ovarian (n = 3), uterine-serous (n = 2), or carcinosarcoma (n = 2) cancer were treated with SBRT...
2016: Frontiers in Oncology
https://www.readbyqxmd.com/read/27905110/distinct-molecular-landscapes-between-endometrioid-and-non-endometrioid-uterine-carcinomas
#3
Nathaniel L Jones, Joanne Xiu, Sudeshna Chatterjee-Paer, Alexandre Buckley de Meritens, William M Burke, Ana I Tergas, Jason D Wright, June Y Hou
Endometrial carcinoma (EC) is traditionally characterized as endometrioid and non-endometrioid based on histo-pathologic phenotypes. Molecular-based classifications have been proposed, but are not widely implemented. Herein we examine molecular profiles between EC histologic subtypes. 3133 ECs were submitted between March 2011 and July 2014: 1634 Type I and 1226 Type II. In situ hybridization and immunohistochemistry were used to assess copy number and protein expression of selected genes. Sequenced variants in 47 genes were analyzed using the Illumina TruSeq Amplicon Cancer Panel...
December 1, 2016: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/27899985/possible-role-of-thymidine-phosphorylase-in-gynecological-tumors-as-an-individualized-treatment-strategy
#4
Masako Shida, Masanori Yasuda, Mariko Fujita, Masaki Miyazawa, Hiroshi Kajiwara, Takeshi Hirasawa, Masae Ikeda, Naruaki Matsui, Toshinari Muramatsu, Mikio Mikami
Thymidine phosphorylase (TP) is structurally similar to platelet-derived endothelial cell growth factor, and it activates 5-fluorouracil (5-FU) prodrugs and also promotes angiogenesis. In the present study, the possibility of using TP expression as a biomarker for 5-FU prodrugs, and the significance of TP as an angiogenic factor, were investigated in patients with gynecological tumors. The subjects enrolled in the study were 188 patients with gynecological tumors who provided informed consent and underwent tumor resection at the Department of Obstetrics and Gynecology of Tokai University Hospital between February 2002 and January 2010...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27899784/-effectiveness-of-carboplatin-plus-taxane-chemotherapy-for-advanced-or-recurrent-uterine-serous-carcinoma
#5
Takuto Matsuura, Isao Otsuka
OBJECTIVE: Uterine serous carcinoma(USC)is more aggressive compared to endometrioid adenocarcinoma, and often exhibits intraperitoneal spread, resulting in a poor prognosis. It is a rare subtype of uterine cancers, accounting for 5%of cases in Japan; therefore, optimal chemotherapy regimens for patients with advanced or recurrent disease have not been established. In the present study, we evaluated the safety and efficacy of carboplatin plus taxane chemotherapy for the treatment of patients withadvanced and recurrent USC...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27817932/population-based-study-of-survival-for-women-with-serous-cancer-of-the-ovary-fallopian-tube-peritoneum-or-undesignated-origin-on-behalf-of-the-swedish-gynecological-cancer-group-swegcg
#6
Pernilla Dahm-Kähler, Christer Borgfeldt, Erik Holmberg, Christian Staf, Henrik Falconer, Maria Bjurberg, Preben Kjölhede, Per Rosenberg, Karin Stålberg, Thomas Högberg, Elisabeth Åvall-Lundqvist
OBJECTIVE: The aim of the study was to determine survival outcome in patients with serous cancer in the ovary, fallopian tube, peritoneum and of undesignated origin. METHODS: Nation-wide population-based study of women≥18years with histologically verified non-uterine serous cancer, included in the Swedish Quality Registry for primary cancer of the ovary, fallopian tube and peritoneum diagnosed 2009-2013. Relative survival (RS) was estimated using the Ederer II method...
November 3, 2016: Gynecologic Oncology
https://www.readbyqxmd.com/read/27798902/genomic-characterisation-and-response-to-trastuzumab-and-paclitaxel-in-advanced-or-recurrent-her2-positive-endometrial-carcinoma
#7
Martin Koskas, Jeroen Depreeuw, Stijn Moens, Daniela Annibali, Tine Cuppens, Philippe Moerman, Diether Lambrechts, Frederic Amant
BACKGROUND/AIM: Human epidermal growth factor receptor 2 (HER2) positivity is associated with a worse prognosis in endometrial cancer (EC). Trastuzumab as a single agent did not demonstrate activity in such cases but there are no reports on its combined use with taxanes. We report the outcome in patients treated simultaneously with trastuzumab and paclitaxel for advanced or recurrent HER2-positive endometrial carcinoma and compared it to their microsatellite instability (MSI) status and PIK3CA mutational profiles...
October 2016: Anticancer Research
https://www.readbyqxmd.com/read/27791010/mutational-landscape-of-uterine-and-ovarian-carcinosarcomas-implicates-histone-genes-in-epithelial-mesenchymal-transition
#8
Siming Zhao, Stefania Bellone, Salvatore Lopez, Durga Thakral, Carlton Schwab, Diana P English, Jonathan Black, Emiliano Cocco, Jungmin Choi, Luca Zammataro, Federica Predolini, Elena Bonazzoli, Mark Bi, Natalia Buza, Pei Hui, Serena Wong, Maysa Abu-Khalaf, Antonella Ravaggi, Eliana Bignotti, Elisabetta Bandiera, Chiara Romani, Paola Todeschini, Renata Tassi, Laura Zanotti, Franco Odicino, Sergio Pecorelli, Carla Donzelli, Laura Ardighieri, Fabio Facchetti, Marcella Falchetti, Dan-Arin Silasi, Elena Ratner, Masoud Azodi, Peter E Schwartz, Shrikant Mane, Roberto Angioli, Corrado Terranova, Charles Matthew Quick, Babak Edraki, Kaya Bilgüvar, Moses Lee, Murim Choi, Amy L Stiegler, Titus J Boggon, Joseph Schlessinger, Richard P Lifton, Alessandro D Santin
Carcinosarcomas (CSs) of the uterus and ovary are highly aggressive neoplasms containing both carcinomatous and sarcomatous elements. We analyzed the mutational landscape of 68 uterine and ovarian CSs by whole-exome sequencing. We also performed multiregion whole-exome sequencing comprising two carcinoma and sarcoma samples from six tumors to resolve their evolutionary histories. The results demonstrated that carcinomatous and sarcomatous elements derive from a common precursor having mutations typical of carcinomas...
October 25, 2016: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/27764792/axl-modulates-extracellular-matrix-protein-expression-and-is-essential-for-invasion-and-metastasis-in-endometrial-cancer
#9
Laura M Divine, Mai R Nguyen, Eric Meller, Riva A Desai, Batool Arif, Erinn B Rankin, Katherine H Bligard, Cherise Meyerson, Ian S Hagemann, Maria Massad, Premal H Thaker, Andrea R Hagemann, Carolyn K McCourt, Matt A Powell, David G Mutch, Katherine C Fuh
The receptor tyrosine kinase AXL promotes migration, invasion, and metastasis. Here, we evaluated the role of AXL in endometrial cancer. High immunohistochemical expression of AXL was found in 76% (63/83) of advanced-stage, and 77% (82/107) of high-grade specimens and correlated with worse survival in uterine serous cancer patients. In vitro, genetic silencing of AXL inhibited migration and invasion but had no effect on proliferation of ARK1 endometrial cancer cells. AXL-deficient cells showed significantly decreased expression of phospho-AKT as well as uPA, MMP-1, MMP-2, MMP-3, and MMP-9...
October 13, 2016: Oncotarget
https://www.readbyqxmd.com/read/27759595/survival-differences-among-uterine-papillary-serous-clear-cell-and-grade-3-endometrioid-adenocarcinoma-endometrial-cancers-a-national-cancer-database-analysis
#10
Mary McGunigal, Jerry Liu, Tamara Kalir, Manjeet Chadha, Vishal Gupta
OBJECTIVES: High-risk histology including UPSC, CC, and high-grade (G3) endometrioid adenocarcinoma (EAC) have a worse prognosis compared to G1-2 EAC. It is unknown whether G3EAC outcomes are more similar to UPSC/CC or to G1-2 EAC. The purpose of this study was to compare overall survival (OS) among UPSC, CC, and G1-3 EAC, for International Federation of Gynecology and Obstetrics stages I to III. METHODS: The National Cancer Data Base was queried for patients diagnosed with International Federation of Gynecology and Obstetrics (1988 classification) Stage I-III UPSC, CC, and EAC from 1998 to 2012 who underwent surgery as definitive treatment...
October 18, 2016: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/27757531/-metastatic-mechanisms-of-uterine-malignancies-and-therapeutic-consequences
#11
S F Lax, K F Tamussino, P F Lang
Malignancies of the uterus metastasize by direct invasion of neighboring structures, lymphatically or hematogenously. Endometrial and cervical cancers lymphatically spread to the pelvic and para-aortic lymph nodes. For endometrial cancer the depth of myometrial invasion, lymphosvascular space involvement (LVSI) and a microcystic, elongated and fragmented (MELF) glandular invasion pattern are predictors for lymph node metastases. Metastases to the pelvic lymph nodes occur in approximately 10 % of endometrial cancer patients and in 30 % of these cases the para-aortic lymph nodes are also involved...
October 18, 2016: Der Pathologe
https://www.readbyqxmd.com/read/27743738/impact-of-histology-and-surgical-approach-on-survival-among-women-with-early-stage-high-grade-uterine-cancer-an-nrg-oncology-gynecologic-oncology-group-ancillary-analysis
#12
Amanda N Fader, James Java, Meaghan Tenney, Stephanie Ricci, Camille C Gunderson, Sarah M Temkin, Nick Spirtos, Christina L Kushnir, Michael L Pearl, Oliver Zivanovic, Krishnansu S Tewari, David O'Malley, Ellen M Hartenbach, Chad A Hamilton, Natalie S Gould, Robert S Mannel, William Rodgers, Joan L Walker
OBJECTIVES: We sought to analyze the clinicopathologic features, recurrence patterns and survival outcomes of women with high-grade uterine cancer (UC) enrolled on The Gynecologic Oncology Group (GOG) LAP2 trial. METHODS: This is a post-hoc analysis of LAP-2 patients with grade 3 endometrioid adenocarcinoma (ENDO), uterine serous (USC), clear cell (CC) and carcinosarcoma (CS). Demographics, clinicopathologic features, and recurrence patterns, were compared by histology and surgical approach...
December 2016: Gynecologic Oncology
https://www.readbyqxmd.com/read/27672676/metastatic-papillary-serous-uterine-cancer-presenting-as-a-rash
#13
Eric S Chang, William D Baker, Charles N Landen
BACKGROUND: We report diagnosis and management of stage IV papillary serous uterine cancer with initial clinical presentation as a skin rash. CASE: A 62-year-old postmenopausal female developed an erythematous rash beginning on her right lower abdomen and progressively spreading to her left abdomen, vulva, and neck. After a trial of antibiotic treatment, biopsy of left neck and right thigh skin nodules revealed papillary serous carcinoma. Abdominopelvic tomography revealed endometrial thickening and a 5 cm left adnexal mass...
November 2016: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/27539290/comparison-of-the-classical-method-and-see-fim-protocol-in-detecting-microscopic-lesions-in-fallopian-tubes-with-gynecological-lesions
#14
Nermin Koc, Selçuk Ayas, Sevcan Arzu Arinkan
Background: The objective of this study was to compare the classical method and Sectioning and Extensively Examining the Fimbriated End Protocol (SEE-FIM) in detecting microscopic lesions in fallopian tubes with gynecological lesions. Materials and Methods: From a total of 1,118 cases, 582 with various parts of both fallopian tubes sampled in three-ring-shape sections and 536 sampled with the SEE-FIM protocol were included in this study. Pathological findings of cases with endometrial carcinoma, non-uterine pelvic malignant tumor, ovarian borderline tumors, premalignancy, and benign lesions were compared...
August 19, 2016: Journal of Pathology and Translational Medicine
https://www.readbyqxmd.com/read/27514313/analysis-of-clinical-and-pathological-characteristics-treatment-methods-survival-and-prognosis-of-uterine-papillary-serous-carcinoma
#15
Ulas Solmaz, Atalay Ekin, Emre Mat, Cenk Gezer, Askin Dogan, Alper Biler, Nuri Peker, Pinar Solmaz Hasdemir, Muzaffer Sanci
PURPOSE: Uterine papillary serous carcinoma (UPSC) is an atypical variant of endometrial carcinoma with a poor prognosis. It is commonly associated with an increased risk of extrauterine disease. The aim of this study was to investigate clinical and pathological characteristics, therapeutic methods, and prognostic factors in women with UPSC. METHODS: All patients who underwent surgery for UPSC at a single high-volume cancer center between January 1995 and December 2010 were retrospectively reviewed...
August 4, 2016: Tumori
https://www.readbyqxmd.com/read/27496441/should-we-be-concerned-about-asymptomatic-adnexal-masses-in-female-kidney-and-liver-graft-recipients
#16
N Mazanowska, D Rajski, B Pietrzak, P Kaminski, M Wielgos
BACKGROUND: Pathological changes of uterine adnexa are frequently encountered in patients after solid-organ transplantation. The aim of the study was to evaluate the incidence of malignancies among recipients operated with the diagnosis of adnexal tumor with or without clinical symptoms. METHODS: We retrospectively analyzed data from 146 solid-organ recipients who underwent surgery in the First Department of Obstetrics and Gynecology, Medical University of Warsaw, in the years 2000 to 2014...
June 2016: Transplantation Proceedings
https://www.readbyqxmd.com/read/27485451/recurrent-ppp2r1a-mutations-in-uterine-cancer-act-through-a-dominant-negative-mechanism-to-promote-malignant-cell-growth
#17
Dorien Haesen, Layka Abbasi Asbagh, Rita Derua, Antoine Hubert, Stefanie Schrauwen, Yana Hoorne, Frédéric Amant, Etienne Waelkens, Anna Sablina, Veerle Janssens
Somatic missense mutations in the Ser/Thr protein phosphatase 2A (PP2A) Aα scaffold subunit gene PPP2R1A are among the few genomic alterations that occur frequently in serous endometrial carcinoma (EC) and carcinosarcoma, two clinically aggressive subtypes of uterine cancer with few therapeutic options. Previous studies reported that cancer-associated Aα mutants exhibit defects in binding to other PP2A subunits and contribute to cancer development by a mechanism of haploinsufficiency. Here we report on the functional significance of the most recurrent PPP2R1A mutations in human EC, which cluster in Aα HEAT repeats 5 and 7...
October 1, 2016: Cancer Research
https://www.readbyqxmd.com/read/27457116/adult-comorbidity-evaluation-27-score-as-a-predictor-of%C3%A2-survival-in-endometrial-cancer-patients
#18
Pratibha S Binder, Jeffrey F Peipert, D Kallogjeri, Rebecca A Brooks, L Stewart Massad, David G Mutch, Matthew A Powell, Premal H Thaker, Carolyn K McCourt
BACKGROUND: The incidence of endometrial cancer increases with age and is associated with medical comorbidities such as obesity and diabetes. Although a few cohort studies of <500 patients showed an association between comorbidity and survival in patients with endometrial cancer, the degree of association must be better described. The Adult Comorbidity Evaluation 27 is a validated comorbidity instrument that provides a score of 0-3 based on the number of and severity of medical comorbidities...
December 2016: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/27453926/performance-of-sentinel-lymph-node-biopsy-in-high-risk-endometrial-cancer
#19
Jessie Ehrisman, Angeles Alvarez Secord, Andrew Berchuck, Paula S Lee, Nicola Di Santo, Micael Lopez-Acevedo, Gloria Broadwater, Fidel A Valea, Laura J Havrilesky
OBJECTIVE: To determine the rate and performance of sentinel lymph node (SLN) mapping among women with high-risk endometrial cancers. METHODS: Patients diagnosed between 2012 and 2015 with uterine cancer of grade 3 endometrioid, clear cell, serous or carcinosarcoma histology and who underwent SLN mapping prior to full pelvic lymph node dissection were included. Subjects underwent methylene blue or ICG injection for laparoscopic (N = 16) or robotic-assisted laparoscopic (N = 20) staging...
August 2016: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/27426853/hormone-therapy-after-prophylactic-risk-reducing-bilateral-salpingo-oophorectomy-in-women-who-have-brca-gene-mutation
#20
F Guidozzi
Women with a BRCA1 or BRCA2 gene mutation have substantially higher risk for developing not only breast and ovarian cancers, but also for primary peritoneal, Fallopian tube, colonic, pancreatic cancers, uterine papillary serous adenocarcinoma and malignant melanoma. The risk for ovarian cancer ranges from 39 to 49% by 70 years of age in BRCA1 mutation carriers and from 11 to 18% for those with a BRCA2 mutation, whilst breast cancer increases similarly within women who have either the BRCA1 mutation or the BRCA2 mutation, from about 20% in women in their forties, 37% by the age of 50 years, 55% by 60 years and more than 70% by the age of 70 years...
October 2016: Climacteric: the Journal of the International Menopause Society
keyword
keyword
16962
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"